Updated on 26 August 2013
Recently, South Korean company, Celltrion, announced receiving positive opinion from the European Medicine's Agency (EMA) for the sale of an infliximab biosimilar in the European Union. With many other biosimilars being developed in Asia, it is forecast that biomanufacturing will continue to scale up throughout the region.
Please elaborate on the major activities of Thermo Fisher in Asia?
Thermo Fisher is one of the largest life sciences companies in the Asia Pacific (APAC) region, which also represents our fastest-growing market. Currently APAC contributes to approximately 17 percent of our revenues (more than US$2 billion annually) and was a major contributor to the company's organic growth last year. Last year marked Thermo Fisher's 30th year in this region and we now have more than 5,000 employees working throughout this region.
Over the last several months, we have crossed many major milestones throughout the Asia Pacific region. Thermo Fisher expanded its global cell culture and bioprocessing capabilities by opening a new manufacturing plant in Singapore to produce dry powder media (DPM). The facility is the first cell culture DPM production site in Singapore and is designed to address the increased global requirements from biopharmaceutical companies to mitigate critical raw material supply risks.
In June 2013, Thermo Fisher opened a new China Innovation Center to support product engineering, development and training in order to meet the specific needs of customers in China and Asia Pacific. Moreover, in 2012, Thermo Fisher opened a new manufacturing facility in Suzhou, primarily dedicated to serving the life sciences and pharmaceutical industries.
In India, Thermo Fisher recently opened a new toll manufacturing facility in 2012 for its global chemicals business that includes a ISO 9001:2008 certified quality analysis (QA) laboratory as well as hazardous chemical storage for bulk solvents.
What are the current trends in biopharmaceutical industry and how is Thermo Fisher positioned to address the changes?
The pharmaceutical industry continues to move rapidly towards large molecule or biologics drug development. As a result, our biopharma customers today face a changing and global landscape with a heightened focus on supply assurance, consistent quality and redundant manufacturing.
Bringing biologic medicines from discovery to development and production, demands exceptional technologies and expertise. Thermo Fisher offers a deep understanding of the complex relationship between single-use film, cell culture media, single-use bioreactors and the biological systems used to produce vaccines and biologics.